Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty

Chinese Medical Journal

Volumn 125, Issue 19, 2012, Pages 3368-3373

  Geng, Wei ^a   Fu, Xiang hua ^a   Gu, Xin shun ^a   Wang, Yan bo ^a   Wang, Xue chao ^a   Li, Wei ^a   Jiang, Yun fa ^a   Hao, Guo zhen ^a   Fan, Wei ze ^a   Xue, Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Angiography; Angioplasty; Anisodamine; Contrast induced nephropathy; Diabetes

Indexed keywords

ANISODAMINE; CREATININE; IODINE; IOPROMIDE; SODIUM CHLORIDE;

AGED; ANGIOCARDIOGRAPHY; ANGIOPLASTY; ARTICLE; CONTINUOUS INFUSION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE; HUMAN; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE;

ACUTE KIDNEY INJURY; AGED; ANGIOPLASTY, BALLOON, CORONARY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SODIUM CHLORIDE; SOLANACEOUS ALKALOIDS;

EID: 84867407618     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.19.002     Document Type: Article

References (36)

1. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.
2. Nikolsky E, Aymong ED, Dangas G, Mehran R. Radiocontrast nephropathy: identifying the high-risk patient and the implications of exacerbating renal function. Rev Cardiovasc Med 2003; 4: Suppl 1: S7-S14.
3. Nikolsky E, Mehran R, Turcot D, Aymong ED, Mintz GS, Lasic Z, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004; 94: 300-305.
4. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006; 113: 1799-1806.
5. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Catheter Cardiovasc Intervent 2001; 52: 409-416.
6. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
7. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989; 320: 143-149.
8. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990; 89: 615-620.
9. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrast induced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003; 15: 18-22.
10. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005; 67: 706-713.
11. Wang A, Holcslaw T, Bashore TM, Freed MI, Miller D, Rudnick MR, et al. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism. Kidney Int 2000; 57: 1675-1680.
12. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6: 1451-1458.
13. Katholi RE, Woods WT Jr, Taylor GJ, Deitrick CL, Womack KA, Katholi CR, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998; 32: 64-71.
14. Xiu RJ, Hammerschmidt DE, Coppo PA, Jacob HS. Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock. JAMA 1982; 247: 1458-1460.
15. Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol 2007; 27: 116-121.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
17. Wang XC, Fu XH, Wang YB, Jia XW, Wu WL, Gu XS, et al. Prediction of contrast-induced nephropathy in diabetics undergoing elective percutaneous coronary intervention: role of the ratio of contrast medium volume to estimated glomerular filtration rate. Chin Med J 2011; 124: 892-896.
18. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010; 55: 2201-2209.
19. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs. sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300: 1038-1046.
20. Chen HH. Atrial natriuretic peptide for the prevention of contrast-induced nephropathy: what's old is new but at the right dose and duration of therapy. J Am Coll Cardiol 2009; 53: 1047-1049.
21. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiologica 2010; 51: 641-648.
22. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, et al. Fenoldopam mesylate for the prevention of contrast induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-2291.
23. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 519-524.
24. Wang YX, Jia YF, Chen KM, Morcos SK. Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers. Br J Radiol 2001; 74: 1103-1108.
25. Huber W, Ilgmann K, Page M, Hennig M, Schweigart U, Jeschke B, et al. Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology 2002; 223: 772-779.
26. Shammas NW, Kapalis MJ, Harris M, McKinney D, Coyne EP. Aminophylline does not protect against radiocontrast nephropathy in patients undergoing percutaneous angiographic procedures. J Invasive Cardiol 2001; 13: 738-740.
27. Gare M, Haviv YS, Ben-Yehuda A, Rubinger D, Bdolah-Abram T, Fuchs S, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999; 34: 1682-1688.
28. LI JH, HE NS. Prevention of iodinated contrast-induced nephropathy. Chin Med J 2011; 124: 4079-4082.
29. Zhao T, Li DJ, Liu C, Su DF, Shen FM. Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway. Front Pharmacol 2011; 2: 23.
30. Fu XH, Fan WZ, Gu XS, Wei YY, Jiang YF, Wu WL, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J 2007; 120: 1226-1231.
31. Zou AP, Parekh N, Steinhausen M. Effect of anisodamine on the microcirculation of the hydronephrotic kidney of rats. Int J Microcirc Clin Exp 1990; 9: 285-296.
32. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol Renal Physiol 1990; 258: F115-F120.
33. Nakagawa S, Kushiya K, Taneike I, Imanishi K, Uchiyama T, Yamamoto T. Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice. Clin Diagn Lab Immunol 2005; 12: 399-408.
34. Esberg LB, Ren J. The oxygen radical generator pyrogallol impairs cardiomyocyte contractile function via a superoxide and p38 MAP kinase-dependent pathway: protection by anisodamine and tetramethylpyrazine. Cardiovasc Toxicol 2004; 4: 375-384.
35. Liu X, Zhang J. An experimental study on the mechanism of anisodamine hydrobromidum in treating acute ischemic renal failure. J Tongji Med Univ 1998; 18: 187-189.
36. Wang YB, Fu XH, Gu XS, Wang XC, Zhao YJ, Hao GZ, et al. Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome. Chin Med J 2012; 125: 1063-1067.